20 growth stocks priced as value stocks

A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight financial services companies, five healthcare names and four in the information technology sector.

Market Watch • Jun 15, 2026

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD. The poster presentation details are as follows: Abstract Title Poster Presentation Session Treatment with Pitolisant in Subgroups of Adults with.

Business Wire • Jun 11, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

Harmony Biosciences to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor.

Business Wire • May 27, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.

Business Wire • May 7, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.78 per share a year ago.

Zacks Investment Research • May 7, 2026

Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet

The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 34.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • May 4, 2026

Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice

Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • May 4, 2026

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • May 4, 2026